Retatrutide has emerged as a new treatment in the fight against obesity. This revolutionary drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in research studies. By boosting these receptors, Retatrutide suppresses appetite, {promotesenergy expenditure, and ultimately leads to significant reduction in body mass.